Plasma-treated L-arginine alters breast cancer cell-derived small extracellular vesicles (sEVs) miR-21 and selectively suppresses cancer cell viability
Year: 2026
Type: preprint
Abstract: This study investigated the selective and sustained inhibitory effects of plasma-treated L-arginine (PTA) on breast cancer cells and explored the potential involvement of small extracellular vesicle (sEV)-mediated intercellular communication. PTA selectively reduced the viability of MCF-7 breast cancer cells compared with MCF-10A normal mammary epithelial cells. To examine whether vesicle-associated signaling contributes to this sustained response, sEVs were isolated from untreated and PTA-treated MCF-7 cells and characterized by nanoparticle tracking analysis, transmission electron microscopy, cellular uptake imaging, and functional assays. sEVs derived from PTA-treated MCF-7 cells retained typical vesicle-like morphology and were efficiently internalized by recipient cells. Functionally, these sEVs selectively suppressed MCF-7 cell viability while exerting limited effects on MCF-10A cells. miRNA analysis further showed that miR-21 expression was decreased by approximately 68% in sEVs derived from PTA-treated MCF-7 cells compared with untreated controls. These findings suggest that PTA may exert sustained anticancer effects, at least in part, by altering cancer cell-derived sEV cargo and modulating vesicle-mediated intercellular signaling. This study provides a potential link between plasma-activated amino acid treatment and sEV-associated regulation of breast cancer cell viability.
Source: Research Square
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7237212885
